Naropin Recall Issued for Particulate Matter
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Fresenius Kabi USA, LLC is recalling 92,600 vials of Naropin (ropivacaine hydrochloride) injection due to the presence of hair particulate matter.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, drugs.
What Happened
Fresenius Kabi USA, LLC initiated a voluntary recall of Naropin due to the presence of particulate matter (hair) found in products.
Which Products Are Affected
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials. NDC Tray: 63323-286-23; NDC Vial: 63323-286-05. Lot #: 6133436, Exp. Date 10/2028. 92,600 vials distributed nationwide within the USA.
What You Should Do
Consumers and healthcare providers should follow guidance from the recalling firm regarding the affected product.
Why This Matters
This Class II recall involves a prescription drug distributed nationwide, with potential for temporary or reversible adverse health consequences.
Source
FDA recall number D-0727-2026, Fresenius Kabi USA, LLC.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (814 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 11, 2026.
Frequently Asked Questions
Common questions about this FDA recall.